Degussa has sold its Boulder, CO-based Proligo Group to life-science company Sigma-Aldrich of St. Louis, MO for an undisclosed purchase price.
Proligo operates in the field of nucleic acids and oligonucleotide synthesis, with sites in Hamburg, Paris, Boulder, Singapore, Kyoto and Lismore/Australia. Annual sales at the company, which employs around 300 staff worldwide, totalled 30.9 million Euros in 2004.
Dussa sold the company because it believed that, with its sixth place ranking in the oligonucleotides market, it did not have the necessary clout to achieve a leading position in a market which is expected to face heavy consolidation. Degussa had been evaluating strategic options for Proligo for the past few months.
One of the world’s leading life-science and high-tech companies, Sigma-Aldrich is seeking to substantially expand its activities in the nucleic acid market, making Proligo a good fit.
Completion of the transaction remains subject to the approval of the German Federal Anti-Trust Office (Bundeskartellamt).